AHA 2010: a selection of the key highlights

The 2010 American Heart Association Scientific Sessions in Chicago (November 13-17) were relatively quiet, with Bayer's Xarelto and Merck's anacetrapib proving to be the main attractions. However, Datamonitor expects that data presented on cardiorenal sydromes, critical limb ischemia, and cachexia in heart failure will also have an impact on the future of cardiovascular drug development.

Published By Datamonitor

Beth Israel: big pharma deal wanted

Published By Datamonitor

Celiac disease: improved diagnosis potential highlights untapped market

A new study has highlighted the benefit of routine antibody testing in suspected cases of celiac disease. While these data prove the merit of serological testing, awareness of the disease remains a significant issue. Indeed, with almost no treatment options available, the development of an effective pharmacological therapy offers the potential to reap significant returns from this untapped market.

Published By Datamonitor

Centocor: ambulance delivery to revive clot-buster sales

Pre-hospital thrombolysis should revitalize sales of thrombolytics, which have seen falling sales since 1998 because PCTA and stenting are more effective. However, the new procedure may be slow to reach the US, because of the high risk of litigation. And even where pre-hospital thrombolysis does take off, the major beneficiary will be Genentech's TNKase.

Published By Datamonitor

Challenging times ahead for US pharma

President Obama's winning of a second term in office places further pressure on the pharma industry, with a more aggressive stance expected towards limiting drug expenditure. However, while the industry may well have fared better under challenger Romney, pharma faced hard times regardless of the outcome of the election.

Published By Datamonitor

Clinical decision support tools set to fundamentally change the way medicine is practiced

Clinical decision support tools, technologies that provide information to aid the diagnosis and treatment of patients, are set to make dramatic changes to the practice of medicine, according to a new report by Datamonitor. However, the report also predicts that aspects of medical culture will prove barriers to adoption.

Published By Datamonitor

Drug reps must embrace technology to avoid missing sales opportunities

In a pharmaceutical market where the days of the primary care blockbuster-selling drug appear numbered, the days of pharma sales representatives having time to visit physicians with drug samples are also waning. Reps must now embrace internet technology to ensure samples are efficiently distributed to physicians and also take on the role of educators in their dynamic relationships with physicians.

Published By Datamonitor

Electronic health records: crucial for a modern healthcare system

Despite the bad publicity surrounding the implementation of electronic health records in some cases, effectively managing patient information will be key to the modernization of today's healthcare systems. Datamonitor expects the overall global electronic health records market to grow to almost $13 billion by 2012 - a compound annual growth rate of 23.8%.

Published By Datamonitor

eProcurement: Medical Columbus may suffer in the New World

Published By Datamonitor

FirstHealth: paying doctors for web visits

Published By Datamonitor